Ubrelvy (ubrogepant) / Merck (MSD), AbbVie  >>  Phase 4
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ubrelvy (ubrogepant) / AbbVie
NCT05264129: Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine

Completed
4
263
US
Atogepant, QULIPTA, Ubrogepant, UBRELVY
AbbVie
Episodic Migraine
04/23
04/23
UNION, NCT05503082: Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies

Active, not recruiting
4
164
US
Ubrogepant 50 MG [Ubrelvy], Ubrogepant 100 MG [Ubrelvy]
Chicago Headache Center & Research Institute, AbbVie
Headache, Migraine
09/24
11/24
2021-001087-24: A study to evaluate the effect of almotriptan and ubrogepant as treatment for an acute migraine attack

Terminated
4
645
Europe
Almotriptan "Sandoz", Ubrogepant, Tablet, Almotriptan "Sandoz"
Danish Headache Center, Danish Headache Center
Migraine, Migraine, Diseases [C] - Nervous System Diseases [C10]
 
 
ATOM, NCT05214001: Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine

Terminated
4
8
Europe
Almotriptan 12.5 Mg Oral Tablet, Almogran, Ubrogepant 50Mg Tab, Ubrelvy
Messoud Ashina, MD
Migraine With Aura, Migraine Without Aura
04/24
04/24

Download Options